Virotherapy: The next addition to the standard of care for glioblastoma? Oct. 3, 2022, 10:29 a.m.
A recent Nature Medicine article reported a phase II single-arm trial assessing the efficacy of a triple-mutated, third-generation oncolytic herpes simplex virus type 1 in patients with recurrent or residual glioblastoma. We discuss the results and highlight the potential of locally administered virus-based therapies to fight these lethal tumors.
MBV nearly $400k to develop Purdue-discovered glioblastoma treatment Sept. 29, 2022, 5:54 p.m.
Monon Bioventures has received funding from the National Cancer Institute to develop a glioblastoma treatment. Monon Bioventures, Genezen and Purdue University pharmacy researcher will partner up to ‘arm’ natural killer cells and prove manufacturability. The work demonstrates that human immune “natural killer” (NK) cells can be “armed” to specifically attack glioblastomas.
Drug Targets Link between Glioblastoma Stem Cells and Circadian Clock Proteins Sept. 29, 2022, 5:53 p.m.
A Keck School of Medicine of USC-led research team has demonstrated that circadian clock proteins, which help to coordinate changes in the body’s functions over the course of a day, may play a key role in glioblastoma growth and proliferation after current standard treatments. The discovery has led to the identification of a small molecule drug, known as SHP656, which can target the clock proteins and may prove effective for treating glioblastoma. The team’s reported study demonstrated that the active isomer of the drug, designated SHP1703, inhibited the growth of patient-derived glioblastoma stem cells (GSCs) in culture.
USC researchers identify drug that may treat cancerous brain tumors Sept. 29, 2022, 5:52 p.m.
The discovery has led to a potential breakthrough: the identification of a small molecule drug, known as SHP656, that can target the clock proteins and may prove effective for treating the disease, according to USC.Biological Sciences at the Keck School of Medicine and director of the USC Michelson Center for Convergent Bioscience.
Evaluation of an online tool about the expected course of disease for glioblastoma patients—A qualitative study Sept. 29, 2022, 5:51 p.m.
Participants considered this tool to be useful and effective in decreasing uncertainties for both patients with glioblastoma and their proxies. Moreover, participants brought up that this tool could positively influence the efficiency and quality of consultations. This could lead to more patient participation and empowerment, and could therefore enhance shared decision making and timely advanced care planning.
At Inflection Point, NovoCure Expands Glioblastoma Portfolio in US Sept. 26, 2022, 10:14 a.m.
NovoCure makes battery-powered skull caps that deliver electrical pulses to treat patients with brain tumors. The company’s technology, Tumor Treating Fields, slows and reverses tumor growth by interfering with cell division.
Developing new gene therapies to treat glioblastoma Sept. 26, 2022, 10:13 a.m.
Immunotherapy has improved outcomes for many cancer patients, but unfortunately, aggressive brain cancers like glioblastoma do not respond to this treatment.
Depletion of reactive astrocytes regresses glioblastoma Sept. 5, 2022, 7:10 a.m.
A groundbreaking study at Tel Aviv University effectively eradicated glioblastoma, a highly lethal type of brain cancer. The researchers achieved the outcome using a method they developed based on their discovery of two critical mechanisms in the brain that support tumor growth and survival: one protects cancer cells from the immune system, while the other supplies the energy required for rapid tumor growth. The work found that both mechanisms are controlled by brain cells called astrocytes, and in their absence, the tumor cells die and are eliminated.
A ground-breaking discovery could eradicate glioblastoma Sept. 5, 2022, 7:10 a.m.
The researchers achieved this ground-breaking discovery by using a method they had previously developed whilst researching two critical mechanisms in the brain. These mechanisms support tumour growth and survival. One protects cancer cells from the immune system, and the other supplies energy to the tumour, allowing rapid growth. The team found that both these mechanisms are controlled by brain cells called astrocytes. In the absence of astrocytes, the tumour cells will die and be permanently eradicated from the brain.
Starving brain tumours for energy: A promising basis for developing effective medications for glioblastoma Sept. 5, 2022, 7:09 a.m.
Dramatic results in glioblastoma research: eliminating the astrocytes (a major class of brain cells) surrounding the tumors or inhibiting their ability to supply energy to the glioblastoma cells resulted in cancer cell death, and tumor regression within several days. “These findings provide a promising basis for developing effective medications for glioblastoma, an aggressive, and thus far incurable cancer, as well as other types of brain tumors.”
Advanced Cell Therapies for Glioblastoma Sept. 5, 2022, 7:07 a.m.
Across the board, regardless of the therapy combination, the five-year survival rate of GBM patients is still very poor at a heartbreaking 5.6%. Obviously, the present situation cannot be tolerated or deemed acceptable. The grave situation calls for researchers to be more innovative and find more efficient strategies to discover new and successful strategies to treat GBM. Inspired by researchers worldwide attempting to control GBM, we provide in this review a comprehensive overview of the many diverse cell therapies currently being used to treat GBM.
CAR T Cell-Based Immunotherapy for the Treatment of Glioblastoma Sept. 5, 2022, 7:04 a.m.
Characterization of GBM cells has contributed to identify several molecules as targets for immunotherapy-based treatments such as EGFR/EGFRvIII, IL13Rα2, B7-H3, and CSPG4. Cytotoxic T lymphocytes collected from a patient can be genetically modified to express a chimeric antigen receptor (CAR) specific for an identified tumor antigen (TA). These CAR T cells can then be re-administered to the patient to identify and eliminate cancer cells. The impressive clinical responses to TA-specific CAR T cell-based therapies in patients with hematological malignancies have generated a lot of interest in the application of this strategy with solid tumors including GBM.
Combined-therapeutic strategies synergistically potentiate glioblastoma multiforme treatment via nanotechnology Sept. 5, 2022, 7:03 a.m.
Numerous therapeutic strategies and delivery systems are developed to prolong the survival time. They exhibit enhanced therapeutic effects in animal models, whereas few of them is applied in clinical trials. Taking into account the drug-resistance and high recurrence of GBM, combined-therapeutic strategies are exploited to maximize therapeutic efficacy. The combined therapies demonstrate superior results than those of single therapies against GBM.
Advances in local therapy for glioblastoma — taking the fight to the tumour Sept. 5, 2022, 7:02 a.m.
Despite advances in neurosurgery, chemotherapy and radiotherapy, glioblastoma remains one of the most treatment-resistant CNS malignancies, and the tumour inevitably recurs. The majority of recurrences appear in or near the resection cavity, usually within the area that received the highest dose of radiation. Many new therapies focus on combatting these local recurrences by implementing treatments directly in or near the tumour bed. In this Review, we discuss the latest developments in local therapy for glioblastoma, focusing on recent preclinical and clinical trials.
What causes brain cancer/glioblastoma cancer ? Sept. 5, 2022, 7 a.m.
Brain cancer is one of the least common forms of cancer, accounting for less than 1% of all cancers. In fact, less than twenty-five percent of people diagnosed with brain cancer survive more than five years. However, it’s important to note that not all cancerous tumours are malignant. Some types can actually be benign. Depending on what type of cancer you have, your treatment plan might differ from these general statistics. Brain tumour treatments are specific to the person and their condition.
The Glioblastoma Brain Cancer Patient Journey DEMYSTIFIED. Aug. 29, 2022, 9:36 a.m.
In this talk Dr. Goueli goes through the ENTIRE GBM cancer patient journey. He discusses clinical trials, molecular testing, current therapies, etc. He very simply explains to patients what treatments they are likely to receive and the side effects associated with them. He teaches patients how to think about their cancer to optimize their chances at success.
Immunology Meets Bioengineering: Improving the Effectiveness of Glioblastoma Immunotherapy Aug. 29, 2022, 9:36 a.m.
Glioblastoma (GBM) therapy has seen little change over the past two decades. Surgical excision followed by radiation and chemotherapy is the current gold standard treatment. Immunotherapy techniques have recently transformed many cancer treatments, and GBM is now at the forefront of immunotherapy research. GBM immunotherapy prospects are reviewed here, with an emphasis on immune checkpoint inhibitors and oncolytic viruses. Various forms of nanomaterials to enhance immunotherapy effectiveness are also discussed.
Next Steps for Immunotherapy in Glioblastoma Aug. 23, 2022, 8:55 a.m.
Prognosis for glioblastoma patients remains poor despite the current standard of care treatments. More recent investigations have focused on immunotherapy, which utilizes a patient’s immune system to target cancer cells. Though proven to be successful in non-central nervous system cancers, immunotherapies have yielded disappointing results for glioblastoma thus far. A variety of factors play into the efficacy of immunotherapy for glioblastoma and have become new areas of interest. Here we review both historical and emerging immunotherapeutic approaches, as well as the molecular factors that have been shown to impact the efficacy of immunotherapies.
Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies Aug. 15, 2022, 3:34 p.m.
Glioblastoma multiforme (GBM) represents the most common and fatal form of primary invasive brain tumors as it affects a great number of patients each year and has a median overall survival of approximately 14.6 months after diagnosis. Despite intensive treatment, almost all patients with GBM experience recurrence, and their 5-year survival rate is approximately 5%. At present, the main clinical treatment strategy includes surgical resection, radiotherapy, and chemotherapy. However, tumor heterogeneity, blood–brain barrier, glioma stem cells, and DNA damage repair mechanisms hinder efficient GBM treatment. The emergence of nanometer-scale diagnostic and therapeutic approaches in cancer medicine due to the establishment of nanotechnology provides novel and promising tools that will allow us to overcome these difficulties.
Functional Precision Oncology: The Next Frontier to Improve Glioblastoma Outcome? Aug. 10, 2022, 8:34 a.m.
Glioblastoma remains the most malignant and intrinsically resistant brain tumour in adults. Despite intensive research over the past few decades, through which numerous potentially druggable targets have been identified, virtually all clinical trials of the past 20 years have failed to improve the outcome for the vast majority of GBM patients. The observation that small subgroups of patients displayed a therapeutic response across several unsuccessful clinical trials suggests that the GBM patient population probably consists of multiple subgroups that probably all require a distinct therapeutic approach. Due to extensive inter- and intratumoral heterogeneity, assigning the right therapy to each patient remains a major challenge. Classically, bulk genetic profiling would be used to identify suitable therapies, although the success of this approach remains limited due to tumor heterogeneity and the absence of direct relationships between mutations and therapy responses in GBM. An attractive novel strategy aims at implementing methods for functional precision oncology, which refers to the evaluation of treatment efficacies and vulnerabilities of (ex vivo) living tumor cells in a highly personalized way.